Provided by Tiger Trade Technology Pte. Ltd.

Travere Therapeutics, Inc.

65.71
+1.251.94%
Pre-market: 65.60-0.1100-0.17%09:13 EDT
Volume:1.62M
Turnover:106.77M
Market Cap:6.19B
PE:-137.92
High:66.38
Open:64.78
Low:64.50
Close:64.46
52wk High:66.38
52wk Low:17.05
Shares:94.26M
Float Shares:92.77M
Volume Ratio:1.30
T/O Rate:1.75%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4764
EPS(LYR):-0.2864
ROE:-236.35%
ROA:-3.73%
PB:252.59
PE(LYR):-229.47

Loading ...

Travere Therapeutics plans offering of $400 million convertible senior notes due 2032

Reuters
·
May 12

Travere Therapeutics Inc - Offers $475 Mln of 0.50% Convertible Senior Notes Due 2032 - SEC Filing

THOMSON REUTERS
·
May 08

BUZZ-U.S. STOCKS ON THE MOVE-Krispy Kreme, Tesla, Axon Enterprise

Reuters
·
May 08

BUZZ-Travere Therapeutics climbs after upsized $475 mln convertible financing

Reuters
·
May 07

BRIEF-Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering To Refinance 2029 Convertible Notes

Reuters
·
May 07

Travere prices upsized USD 475 million convertible senior notes due 2032

Reuters
·
May 07

Travere Therapeutics director Roy D. Baynes sells 4,500 shares for $209,925

Reuters
·
May 07

Travere CMO Jula Inrig disposes 22,485 shares for $1.01 million

Reuters
·
May 07

Travere Therapeutics CLO Elizabeth Reed disposes of shares worth $1.1 million

Reuters
·
May 07

Travere CFO Christopher R. Cline disposes 2,491 shares worth $115,287.45

Reuters
·
May 07

Travere Therapeutics director Jeffrey A. Meckler disposes 8,000 shares for $360,000

Reuters
·
May 07

Wells Fargo Remains a Buy on Travere Therapeutics (TVTX)

TIPRANKS
·
May 06

Travere Therapeutics announces $400M convertible senior notes offering

TIPRANKS
·
May 06

Travere Therapeutics plans USD 400 million convertible senior notes offering due 2032

Reuters
·
May 06

Travere Therapeutics Inc - to Offer $400 Mln Convertible Senior Notes Due 2032

THOMSON REUTERS
·
May 06

Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes

THOMSON REUTERS
·
May 06

Evercore ISI Keeps Their Buy Rating on Travere Therapeutics (TVTX)

TIPRANKS
·
May 05

Stock Track | Travere Therapeutics Soars 5.99% Intraday on Multiple Analyst Price Target Raises

Stock Track
·
May 05

Travere Therapeutics Inc : Jefferies Raises Target Price to $54 From $50

THOMSON REUTERS
·
May 05

Piper Sandler Reaffirms Their Buy Rating on Travere Therapeutics (TVTX)

TIPRANKS
·
May 05